Rituparna Chakrabarti1, Bhavya Kapse2, Gayatri Mukherjee1. 1. School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India. 2. Department of Biotechnology, Indian Institute of Technology Kharagpur, Kharagpur, India.
Abstract
BACKGROUND: With the recent advances in the understanding of the interaction of the immune system with developing tumor, it has become imperative to consider the immunological parameters for both cancer diagnosis and disease prognosis. Additionally, in the era of emerging immunotherapeutic strategies in cancer, it is very important to follow the treatment outcome and also to predict the correct immunotherapeutic strategy in individual patients. There being enormous heterogeneity among tumors at different sites or between primary and metastatic tumors in the same individual, or interpatient heterogeneity, it is very important to study the tumor-immune interaction in the tumor microenvironment and beyond. Importantly, molecular tools and markers identified for such studies must be suitable for monitoring in a noninvasive manner. RECENT FINDINGS: Recent studies have shown that the immune checkpoint molecules play a key role in the development and progression of tumors. In-depth studies of these molecules have led to the development of most of the cancer immunotherapeutic reagents that are currently either in clinical use or under different phases of clinical trials. Interestingly, many of these cell surface molecules undergo alternative splicing to produce soluble isoforms, which can be tracked in the serum of patients. CONCLUSIONS: Several studies demonstrate that the serum levels of these soluble isoforms could be used as noninvasive markers for cancer diagnosis and disease prognosis or to predict patient response to specific therapeutic strategies.
BACKGROUND: With the recent advances in the understanding of the interaction of the immune system with developing tumor, it has become imperative to consider the immunological parameters for both cancer diagnosis and disease prognosis. Additionally, in the era of emerging immunotherapeutic strategies in cancer, it is very important to follow the treatment outcome and also to predict the correct immunotherapeutic strategy in individual patients. There being enormous heterogeneity among tumors at different sites or between primary and metastatic tumors in the same individual, or interpatient heterogeneity, it is very important to study the tumor-immune interaction in the tumor microenvironment and beyond. Importantly, molecular tools and markers identified for such studies must be suitable for monitoring in a noninvasive manner. RECENT FINDINGS: Recent studies have shown that the immune checkpoint molecules play a key role in the development and progression of tumors. In-depth studies of these molecules have led to the development of most of the cancer immunotherapeutic reagents that are currently either in clinical use or under different phases of clinical trials. Interestingly, many of these cell surface molecules undergo alternative splicing to produce soluble isoforms, which can be tracked in the serum of patients. CONCLUSIONS: Several studies demonstrate that the serum levels of these soluble isoforms could be used as noninvasive markers for cancer diagnosis and disease prognosis or to predict patient response to specific therapeutic strategies.
Authors: Barbara Tringler; Wenhui Liu; Laura Corral; Kathleen C Torkko; Takayuki Enomoto; Susan Davidson; M Scott Lucia; David E Heinz; Jackie Papkoff; Kenneth R Shroyer Journal: Gynecol Oncol Date: 2005-10-26 Impact factor: 5.482
Authors: A Younes; V Snell; U Consoli; K Clodi; S Zhao; J L Palmer; E K Thomas; R J Armitage; M Andreeff Journal: Br J Haematol Date: 1998-01 Impact factor: 6.998
Authors: J A Ledbetter; J B Imboden; G L Schieven; L S Grosmaire; P S Rabinovitch; T Lindsten; C B Thompson; C H June Journal: Blood Date: 1990-04-01 Impact factor: 22.113
Authors: Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245
Authors: Frank J Ward; Lekh N Dahal; Subadra K Wijesekera; Sultan K Abdul-Jawad; Taniya Kaewarpai; Heping Xu; Mark A Vickers; Robert N Barker Journal: Eur J Immunol Date: 2013-03-06 Impact factor: 5.532